N/A N=35 Vitreous Inflammation in Standard and Heavy Silicone Oil
Vitreous Inflammation
Primary: Vitreous Prostaglandin E2 Levels — 369.38; 869.16 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
Vitrectomy
Primary: Percentage of Participants With Vitreous Cell Count of 0 — 88.0 Percentage of participants
Phase 2 N=7 Lucentis for Inflammatory Macular Edema Trial
Uveitis · Cytoid Macular Edema
Primary: The Mean Change at 3 Months in BSCVA From Baseline — 13 letters
N/A N=5 Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Uveitis · Cystoid Macular Edema
Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants
Phase 2 N=101 Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME
Diabetic Macular Edema
Primary: Number of Participants With Intraocular Inflammation — 6; 10 Participants
Phase 2 N=12 Aflibercept Injection for Proliferative Diabetic Retinopathy
Vitreous Hemorrhage
Primary: Rate of Resolved Post-operative Vitreous Hemorrhage. — 6; 5 Participants
Phase 2 N=100 Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
Neovascular Age-Related Macular Degeneration
Primary: Evidence of Anterior Chamber Inflammation — 1; 10; 0; 1 participants
Phase 3 N=129 Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
Non-Infectious Uveitis
Primary: Proportion of Subjects With Recurrence of Uveitis in the Study Eye and Overall Summary of Number of Participants With Ocular Treatment-Emergent Adverse Events for the…
N/A N=126 Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy
Proliferative Diabetic Retinopathy · Vitreous Hemorrhage
Primary: Recurrent VH Incidence (Early and Late) — 22.2; 10.8; 32.4; 11.1 Percentage of participants — p=<0.05
Phase 4 N=21 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment
Uveitis
Primary: Number of Eyes With Inflammation Recurrence — 1 eye with inflammation
Phase 3 N=205 Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
Proliferative Diabetic Retinopathy · Vitreous Hemorrhage
Primary: E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline) — 59.3; 63.0 units on a scale
Phase 4 N=5 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
Uveitis · Anterior Uveitis · Intermediate Uveitis
Primary: Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps Documented With Fundus Photography — 3; 1; 1 Participants
Phase 3 N=592 Study Assessing Double-masked Uveitis Treatment
Uveitis; Posterior, Disorder
Primary: The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5 — 28; 44; 27 Participants
Phase 3 N=153 Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis
Posterior Uveitis · Intermediate Uveitis · Panuveitis
Primary: Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months — 28; 22 Participants
Phase 2 N=5 Topical Interferon Gamma for Macular Edema Secondary to Uveitis
Anterior Uveitis · Uveitis
Primary: Change in Excess Central Macular Thickening in the Study Eye, as Measured by Optical Coherence Tomography (OCT), at Week One Compared to Baseline — -38.60 µm
Phase 1 N=6 Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema
Uveitic Cystoid Macular Edema
Primary: Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months. — 12.2 Change in ETDRS Letters — p=0.0015
Phase 2 N=25 Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
Non-infectious Intermediate Uveitis · Non-infectious Posterior Uveitis · Non-infectious Panuveitis
Primary: Number of Participants With Response Rate for the Individual Response Criteria - in the Study Eye — 3; 3; 0; 1 Participants
Phase 3 N=394 The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Inflammation · Cataracts
Primary: Number of Participants With Anterior Chamber Cell Clearing — 99; 103; 20 Participants
N/A N=120 Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics
Bacterial Resistance
Primary: Number of Participants With Resistance of Ocular Flora to Commonly Used Post-injection Prophylactic Antibiotics — 10; 6 Participants
Phase 4 N=129 Topical Antibiotics and Intravitreous Injections
Intravitreous · Injections
Primary: Positive Culture — 8 percentage of patients
Phase 4 N=64 Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
Cataract
Primary: The Percentage of Patients With a Score of Zero for Anterior Chamber Cells. — 91.7 Percentage of participants
Phase 1 N=40 Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
Intravitreal Bevacizumab Injection · Pars Plana Vitrectomy · Tractional Retinal Detachment
Primary: Best Corrected Visual Acuity — 1.1; 1.4 LogMar
Phase 3 N=229 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
Intermediate Uveitis · Posterior Uveitis
Primary: Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero — 35.5; 46.8; 11.8 Percentage of Patients
N/A N=87 Evaluation of Vitrectomy for Diabetic Macular Edema
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Visual Acuity — 52 Units on a scale
Phase 3 N=46 Effects of Pneumatic Vitreolysis on Vitreomacular Traction
Vitreomacular Traction
Primary: Proportion of Eyes With Central Vitreomacular Traction Release Without Rescue Vitrectomy — 78; 9 percentage of eyes
Phase 3 N=38 Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
Uveitis · Uveitis, Posterior · Uveitis, Anterior
Primary: Adverse Events — 27; 1 Participants
Phase 2 N=12 A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis
Non-infectious Uveitis
Primary: Evaluation of Safety and Tolerability by Determining Treatment Emergent Adverse Events — 12 Participants
Phase 4 N=52 Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
Vitreomacular Traction · Vitreomacular Adhesion
Primary: Percentage of Subjects With Non-surgical Resolution of Focal VMT/sVMA at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain Optical Coherence…
Phase 4 N=112 Isotretinoin for Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy
Primary: Rate of Retinal Attachment — 50; 42 Participants
N/A N=100 Evaluation of Retinal Microvascular Change That May Develop in After Open Globe Injury
Eye Injury Trauma
Primary: Corneal Thickness — 542.23; 546.16; 544.32 microns